GE Healthcare has signed a strategic partnership agreement with Danish contract research organization Minerva Imaging aimed at developing targeted radionuclide therapies, also known as theranostics.
Under the deal, GE and Minerva will jointly establish a center for molecular imaging and clinical development of targeted radionuclide therapies. Set to open in 2022, the new facility will expand Minerva's R&D footprint by 50% and will add over 100 employees, the company said.
Specifically, the partnership will establish in-house isotope production capabilities and contract manufacturing organization services for radiopharmaceuticals, the companies said. Minerva will be utilizing a GE cyclotron for isotope production, and GE will assist Minerva to set up good manufacturing practice (GMP) production in the new facility. In addition, GE and Minerva will partner to optimize manufacturing protocols for new radioisotopes, according to the vendors.